keyword
MENU ▼
Read by QxMD icon Read
search

braf thyroid

keyword
https://www.readbyqxmd.com/read/28943919/braf-v600e-mutation-is-not-associated-with-central-lymph-node-metastasis-in-all-patients-with-papillary-thyroid-cancer-different-histological-subtypes-and-preoperative-lymph-node-status-should-be-taken-into-account
#1
Si-Yang Dong, Rui-Chao Zeng, Lang-Ping Jin, Fan Yang, Xiang-Jian Zhang, Zhi-Han Yao, Xiao-Hua Zhang, Ou-Chen Wang
The association between central lymph node metastasis (LNM) and risk factors, including the presence of the BRAF mutation, BRAF(V600E), in patients with papillary thyroid cancer (PTC) requires further investigation. A potent risk factor that can indicate LNM in different histological subtypes of PTC and in different preoperative central lymph node statuses also requires further research. A total of 287 patients with PTC who accepted thyroidectomy were included in the present study. Clinicopathological data of these patients were reviewed to examine the risk factors for central LNM through univariate and multivariate analyses...
October 2017: Oncology Letters
https://www.readbyqxmd.com/read/28940583/molecular-genotyping-of-noninvasive-encapsulated-follicular-variant-of-papillary-thyroid-carcinoma
#2
Tae Hyuk Kim, Minju Lee, Ah-Young Kwon, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Soo Yeon Hahn, Jung Hee Shin, Man Ki Chung, Young Ik Son, Chang-Seok Ki, Hyun Sook Yim, Yoo-Li Kim, Jae Hoon Chung, Sun Wook Kim, Young Lyun Oh
AIM: Noninvasive encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) has been managed as low-risk malignancy. Recently, a proposal was made to reclassify this tumor type as a premalignant lesion and rename it noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). However, a comprehensive study on molecular genotype-phenotype correlations of encapsulated FVPTC is lacking. METHODS AND RESULTS: This study consisted of 177 consecutive FVPTCs from January 2014 to April 2016...
September 20, 2017: Histopathology
https://www.readbyqxmd.com/read/28931558/pathological-processes-and-therapeutic-advances-in-radioiodide-refractory-thyroid-cancer
#3
Marika H Tesselaar, Jan Wa Smit, James Nagarajah, Romana T Netea-Maier, Theo S Plantinga
Whereas in most patients with non-medullary thyroid cancer (TC) disease remission is achieved by thyroidectomy and ablation of tumor remnants by radioactive iodide (RAI), a substantial subgroup of patients with metastatic disease present tumor lesions that have acquired RAI resistance as a result of dedifferentiation. Although oncogenic mutations in BRAF, TERT promoter and TP53 are associated with an increased propensity for induction of dedifferentiation, the role of genetic and epigenetic aberrations and their effects on important intracellular signaling pathways is not yet fully elucidated...
September 20, 2017: Journal of Molecular Endocrinology
https://www.readbyqxmd.com/read/28931215/berberine-could-inhibit-thyroid-carcinoma-cells-by-inducing-mitochondrial-apoptosis-g0-g1-cell-cycle-arrest-and-suppressing-migration-via-pi3k-akt-and-mapk-signaling-pathways
#4
Liang Li, Xingchun Wang, Rampersad Sharvan, Jingyang Gao, Shen Qu
Berberine, an important natural isoquinoline alkaloid from traditional Chinese medicine, is reported to exhibit multiple pharmacological properties, including anti-microbial, anti-diabetes, anti-obesity, anti-inflammatory and anti-carcinogenic activities. Although studies have shown that a wide range of carcinoma cells could be inhibited by berberine, few studies involved thyroid carcinoma. We therefore examined the effect of berberine on papillary thyroid carcinoma (PTC, the most common subtype) and anaplastic thyroid carcinoma (ATC, the most malignant and aggressive subtype)...
September 16, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28928829/braf-v600e-mutation-contributes-papillary-thyroid-carcinoma-and-hashimoto-thyroiditis-with-resistance-to-thyroid-hormone-a-case-report-and-literature-review
#5
Wanjia Xing, Xiaohong Liu, Qingqing He, Zongjing Zhang, Zhaoshun Jiang
Resistance to thyroid hormone (RTH) is a rare autosomal hereditary disorder characterized by increased serum thyroid hormone (TH) levels with unsuppressed or increased thyrotropin concentration. It remains unknown whether the coexistence of RTH with papillary thyroid carcinoma (PTC) and Hashimoto thyroiditis (HT) is incidental or whether it possesses a genetic or pathophysiological association. In the present study, a case of RTH with PTC and HT in an 11-year-old Chinese patient was examined and the clinical presentation of RTH with PTC was discussed...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28915656/patterns-and-clinical-significance-of-cervical-lymph-node-metastasis-in-papillary-thyroid-cancer-patients-with-delphian-lymph-node-metastasis
#6
Guibin Zheng, Hua Zhang, Shaolong Hao, Chengxin Liu, Jie Xu, Jinyao Ning, Guochang Wu, Lixin Jiang, Guojun Li, Haitao Zheng, Xicheng Song
Although the roles of Delphian lymph node (DLN) metastasis in papillary thyroid cancer (PTC) have been previously reported, there are still limited data on correlations of clinicopathologic factors with DLN metastasis and unique patterns of cervical node subsite metastasis in PTC patients with DLN metastasis. We retrospectively reviewed medical records of 320 patients with a diagnosis of PTC who underwent primary surgery. Clinicopathologic features and DLN metastasis patterns were analyzed for predicting extensive cervical lymph node metastasis...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28910894/-diagnostic-values-of-braf-v600e-mutation-analysis-and-bethesda-system-for-reporting-thyroid-cytopathology-in-thyroid-nodules-with-tirads-4-and-5
#7
Y Han, B W Zhao, S Y Li, J G Lyu, J D Shou, H S Xu, H Y Lou, L L Xu, L Gao, S X Xu, J Zhu
Objective: To evaluate the diagnostic efficacies of BRAF(V600E) testing and Bethesda system for reporting thyroid cytopathology (BSRTC) in thyroid nodules with thyroid imaging reporting and data system (TIRADS) category 4 and 5. Methods: A total of 187 thyroid nodules in 187 patients underwent the examinations of ultrasound-guided fine needle aspiration cytology (FNAC) and BRAF(V600E) mutation were analyzed retrospectively. Receive operating characteristic (ROC) curve was used to investigate the diagnostic values of both methods and the clinical application of BRAF(V600E) combined with BSRTC was evaluated...
September 7, 2017: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/28910386/dusp5-and-dusp6-two-erk-specific-phosphatases-are-markers-of-a-higher-mapk-signaling-activation-in-braf-mutated-thyroid-cancers
#8
Camille Buffet, Karine Hecale-Perlemoine, Léopoldine Bricaire, Florent Dumont, Camille Baudry, Frédérique Tissier, Jérôme Bertherat, Beatrix Cochand-Priollet, Marie-Laure Raffin-Sanson, Françoise Cormier, Lionel Groussin
BACKGROUND: Molecular alterations of the MAPK pathway are frequently observed in papillary thyroid carcinomas (PTCs). It leads to a constitutive activation of the signalling pathway through an increase in MEK and ERK phosphorylation. ERK is negatively feedback-regulated by Dual Specificity Phosphatases (DUSPs), especially two ERK-specific DUSPs, DUSP5 (nuclear) and DUSP6 (cytosolic). These negative MAPK regulators may play a role in thyroid carcinogenesis. METHODS: MAPK pathway activation was analyzed in 11 human thyroid cancer cell lines...
2017: PloS One
https://www.readbyqxmd.com/read/28899685/the-tumor-promoting-role-of-trip4-in-melanoma-progression-and-its-involvement-in-response-to-braf-targeted-therapy
#9
Jiaojiao Hao, Hua Xu, Meihua Luo, Wendan Yu, Miao Chen, Yina Liao, Changlin Zhang, Xinrui Zhao, Wei Jiang, Shuai Hou, Xu Feng, Kun Zou, Yiming Chen, Wenlin Huang, Wei Guo, Lan Kang, Wuguo Deng
Thyroid Hormone Receptor Interactor 4 (TRIP4) was identified with anti-proliferative effect in melanoma cells based on siRNA library screening, however, its precise function in melanoma progression is completely unknown. Here, we explored the carcinogenic role of TRIP4 in melanoma. The high expression of TRIP4 was observed in human melanoma cells and tissues. Its knockdown suppressed melanoma progression in vitro and in vivo, including melanoma cell proliferation, migration and invasion inhibition, and apoptosis induction...
September 9, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28881369/-molecular-pathogenesis-of-thyroid-nodules-relevance-for-clinical-care
#10
D Führer, T Musholt, K W Schmid
Thyroid nodules represent heterogeneous tumors with distinct molecular signatures. While benign thyroid nodules correspond to poly- or monoclonal tumors, thyroid carcinomas are monoclonal and thus "real" neoplasms. These are caused by somatic mutations that lead to the constitutive activation of specific signaling cascades and determine the corresponding histology and also partly the functional phenotype of the thyroid tumor. Dedifferentiation of thyroid carcinomas is accompanied by the occurrence of additional mutations in the tumors...
September 2017: Laryngo- Rhino- Otologie
https://www.readbyqxmd.com/read/28879519/safety-tolerability-and-pharmacokinetic-profile-of-dabrafenib-in-japanese-patients-with-braf-v600-mutation-positive-solid-tumors-a-phase-1-study
#11
Yutaka Fujiwara, Naoya Yamazaki, Yoshio Kiyohara, Shusuke Yoshikawa, Noboru Yamamoto, Arata Tsutsumida, Hiroshi Nokihara, Kenjiro Namikawa, Akihira Mukaiyama, Fanghong Zhang, Tomohide Tamura
Background Dabrafenib is a BRAF inhibitor that has demonstrated clinical activity with a good tolerability profile in patients with BRAF (V600E) mutated metastatic melanoma. This study evaluated the safety and tolerability, pharmacokinetics and preliminary efficacy of dabrafenib in Japanese patients. Methods This phase I, open-label, dose escalation study was conducted in 12 Japanese patients with BRAF (V600) mutation positive solid tumours. Primary endpoint was safety, assessed by monitoring and recording of all adverse events (AEs), serious AEs, drug-related AEs; secondary endpoints were pharmacokinetic profiles and efficacy measured by tumour response...
September 7, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28877096/clinical-parameter-for-deciding-the-brafv600e-mutation-test-in-atypia-of-undetermined-significance-follicular-lesion-of-undetermined-significance-thyroid-nodules-us-features-according-to-tirads
#12
Miribi Rho, Eun-Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Vivian Y Park, Kyunghwa Han, Jin Young Kwak
This study aimed to investigate the usefulness of a thyroid imaging reporting and data system (TIRADS) to select thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) cytology for additional BRAF mutation testing. Three hundred three thyroid nodules were included. Statistical analysis was performed at both patient and nodule levels according to BRAF mutation positivity and clinical factors. Univariate and multivariate logistic regression analyses were performed to assess independent associations between BRAF mutation positivity and clinical factors...
September 4, 2017: Ultrasound Quarterly
https://www.readbyqxmd.com/read/28875621/rare-manifestations-of-anaplastic-thyroid-carcinoma-the-role-of-braf-mutation-analysis
#13
Young Shin Song, Chan Kwon Jung, Kyeong Cheon Jung, Young Joo Park, Jae Kyung Won
Anaplastic thyroid carcinoma (ATC) is difficult to distinguish from other cancers, especially when its pathological features are atypical for ATC or when the tumor is totally undifferentiated and occurs after a considerable lapse of time, in an area remote from the original site of the tumor. Here, we present two patients (68-year-old man and 56-year-old woman) with rare manifestations of ATC, which were initially thought to be other malignancies. Immunohistochemical tests, using various markers, failed to provide information about the origin of these tumors...
October 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/28830935/differences-in-mirna-expression-profiles-between-wild-type-and-mutated-niftps
#14
Maria Denaro, Clara Ugolini, Anello Marcello Poma, Nicla Borrelli, Gabriele Materazzi, Paolo Piaggi, Massimo Chiarugi, Paolo Miccoli, Paolo Vitti, Fulvio Basolo
Noninvasive encapsulated follicular variants of papillary thyroid carcinomas have been recently reclassified as noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs). NIFTPs exhibit a behavior that is very close to that of follicular adenomas but different from the infiltrative and invasive follicular variants of papillary thyroid carcinomas (FVPTCs). The importance of miRNAs to carcinogenesis has been reported in recent years. miRNAs seem to be promising diagnostic and prognostic molecular markers for thyroid cancer, and the combination of miRNA expression and mutational status might improve cytological diagnosis...
October 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28808756/relationship-between-18-f-fluorodeoxyglucose-accumulation-and-the-braf-v600e-mutation-in-papillary-thyroid-cancer
#15
Jae Won Chang, Ki Wan Park, Jae Hyung Heo, Seung-Nam Jung, Lihua Liu, Sung Min Kim, In Sun Kwon, Bon Seok Koo
BACKGROUND: To determine whether (18)F-fluoro-2-deoxyglucose ((18)F-FDG)-PET/CT is useful for predicting the BRAF (V600E) mutation status of a primary papillary thyroid carcinoma (PTC). METHODS: A retrospective analysis was performed in 108 patients who underwent (18)F-FDG positron emission tomography-computed tomography (PET/CT) for staging before thyroidectomy and BRAF analysis in biopsy-confirmed PTC. The maximum standardized uptake value (SUVmax) of the primary tumor was calculated according to FDG accumulation...
August 14, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28805135/intermittent-dosing-of-dabrafenib-and-trametinib-in-metastatic-braf-v600e-mutated-papillary-thyroid-cancer-two-case-reports
#16
Paul S White, Anita Pudusseri, Stephanie L Lee, Omar Eton
BACKGROUND: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to achieve more durable response, while being better tolerated and more cost effective. PATIENTS: Two consecutive patients with symptomatic, metastatic radioactive iodine-resistant BRAF(V600E) mutated papillary thyroid cancer and poor performance status were treated initially with dabrafenib 150 mg twice daily plus trametinib 2 mg once daily, first in continuous daily dosing, then in a five-week-on and three-week-off schedule...
September 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28791253/potential-role-of-metabolic-intervention-in-the-management-of-advanced-differentiated-thyroid-cancer
#17
Sri Harsha Tella, Anuhya Kommalapati, Mary Angelynne Esquivel, Ricardo Correa
Well-differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy that has an excellent prognosis with a 5-year survival rate of about 98%. However, approximately 50% of the patients with DTC who present with distant metastases (advanced DTC) die from the disease within 5 years of initial diagnosis even after getting the appropriate therapy. Apart from recent advancements in chemotherapy agents, the potential role of metabolic interventions, including the use of metformin, ketogenic diet, and high-dose vitamin C in the management of advanced cancers have been investigated as a less toxic co-adjuvant therapies...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28780248/invasive-follicular-variant-of-papillary-thyroid-cancer-harboring-the-nras-mutation-q61k-and-presenting-with-bone-metastasis-a-case-report
#18
Raman Mehrzad, Michiya Nishino, Carmelo Nucera, Dora Dias-Santagata, James V Hennessey, Per-Olof Hasselgren
INTRODUCTION: The follicular variant of papillary thyroid cancer (FVPTC) can be noninvasive or invasive. The invasive form of FVPTC commonly harbors BRAF mutations whereas RAS mutations are more often associated with noninvasive FVPTC and a favorable clinical outcome. CASE REPORT: A 47-year-old man presented with a metastasis to his right iliac bone as the initial manifestation of a 1.6cm invasive FVPTC. After total thyroidectomy, the patient underwent additional treatment, including thyroid hormone suppressive treatment to non-detectable TSH levels, repeated courses of radioiodine treatment, external beam radiation, and treatment with the tyrosine kinase inhibitor sorafenib...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28772138/exposure-to-flame-retardant-chemicals-and-occurrence-and-severity-of-papillary-thyroid-cancer-a-case-control-study
#19
Kate Hoffman, Amelia Lorenzo, Craig M Butt, Stephanie C Hammel, Brittany Bohinc Henderson, Sanziana A Roman, Randall P Scheri, Heather M Stapleton, Julie Ann Sosa
BACKGROUND: Thyroid cancer is the fastest increasing cancer in the U.S., and papillary thyroid cancer (PTC) accounts for >80% of incident cases. Increasing exposure to flame retardant chemicals (FRs) has raised concerns about their possible role in this 'epidemic'. The current study was designed to test the hypothesis that higher exposure to FRs is associated with increased odds of PTC. METHODS: PTC patients at the Duke Cancer Institute were approached and invited to participate...
July 31, 2017: Environment International
https://www.readbyqxmd.com/read/28769567/thyroid-cancer-in-a-patient-with-lynch-syndrome-case-report-and-literature-review
#20
Monika Fazekas-Lavu, Andrew Parker, Allan D Spigelman, Rodney J Scott, Richard J Epstein, Michael Jensen, Katherine Samaras
Lynch syndrome describes a familial cancer syndrome comprising germline mutations in one of four DNA mismatch repair genes, MLH1, MSH2, MSH6, and PMS2 and is characterized by colorectal, endometrial, and other epithelial malignancies. Thyroid cancer is not usually considered to be part of the constellation of Lynch syndrome cancers nor have Lynch syndrome tumor gene mutations been reported in thyroid malignancies. This study reports a woman with Lynch syndrome (colonic cancer and a DNA mismatch repair mutation in the MSH2 gene) with a synchronous papillary thyroid cancer...
2017: Therapeutics and Clinical Risk Management
keyword
keyword
17698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"